Diagnovus Acquired by Aegis Sciences Corporation

Aegis Sciences Corporation, one of the nation’s leading laboratory sciences companies, announced today the acquisition of Diagnovus LLC, a molecular diagnostics laboratory providing individualized genetic information, which fundamentally changes the way physicians treat patients.

“The asset acquisition of Diagnovus allows Aegis to expand our healthcare laboratory testing services,” stated Aegis Founder, Chairman, and CEO Dr. David L. Black. “The delivery of patient-specific genetic information to physicians will improve management of disease and prescribing of necessary medication.”

Diagnovus has developed multiple molecular diagnostic assays, including a buccal swab test, which provides insight into an individual’s response to certain medications based on genetic structure. This valuable information may increase the quality of care by reducing the time required to find the optimal course of treatment. In addition to this testing, Diagnovus will continue to offer its hematology/oncology testing using next-generation sequencing, as well as its growing pharmaceutical contract business for Aegis.

“As a scientist and entrepreneur, I am proud to have our team join Aegis,” stated Diagnovus President and Co-Founder, Dr. James Stover. “Aegis’ reputation and client base will allow us to offer our developed molecular diagnostic testing services to a much larger patient population.”

About Aegis Sciences Corporation

Aegis Sciences Corporation is a toxicology laboratory specializing in forensic and healthcare services that provides science-driven testing and consulting for clients, such as professional and amateur sports organizations, distinguished college and university athletic programs, healthcare professionals, Fortune 500 companies, medical examiners, and government agencies throughout the United States.

About Diagnovus

Based in Nashville, Tenn., Diagnovus is a specialized molecular diagnostic company focused on delivering personalized information and services to physicians treating patients suffering from underserved, aggressive, and lesser-known diseases. Its mission is to improve the health of patients and quality of treatment decisions through innovative molecular diagnostics that better inform physicians, patients, and their families facing these difficult disease prospects. Diagnovus was founded in 2011 by two funds affiliated with the TNInvestco program—Tri-Star Technology Fund, LLC, and Limestone Fund, LLC—and Dr. James Stover.